A Case For List Price Cuts? Study Highlights Reduced 340B Liability For Hep C Drugs
Executive Summary
Lower list prices for Epclusa, Harvoni, and Zepatier might actually boost revenue by reducing 340B discounts, but rebate-eschewing dynamic may not expand beyond them because of different exposures to 340B in other classes – and the pending HHS rebate rule.